TABLE 4.

ABR for PwHA treated with emicizumab by ADA status ^a

	ADA‐negative PwHA (N = 634)	ADA‐positive PwHA b (N = 30)	ADA‐positive PwHA with decreased exposure  (N = 4)
Duration of efficacy period Median [IQR], weeks	103 [84‐150]	103 [78‐160]	57 c [16; 65; 80; 50]
Annualised rate of treated bleeding events Model‐based d [95% CI]	.9 [.79‐1.11]	.7 [.37‐1.33]	14.1 c [23.0; 28.0; 0; 5.3]
Proportion of participants with zero treated bleeds, n (%) [95% CI e ]	374 (59.0) [55.1‐62.9]	16 (53.3) [34.3‐71.7]	1 (25.0) [.6‐80.6]
Annualised rate of all bleeding events Model‐based d [95% CI]	2.3 [1.99‐2.60]	1.2 [.75‐1.91]	15.2 c [23.0; 28.0; 0; 7.4]
Proportion of participants with zero all bleeds n (%) [95% CI e ]	224 (35.3) [31.6‐39.2]	7 (23.3) [9.9‐42.3]	1 (25.0) [.6‐80.6]

Abbreviations: ABR, annualised bleed rate; ADA, anti‐drug antibody; CI, confidence interval; IQR, interquartile range; PwHA, persons with haemophilia A.

^a Data includes the up‐titration period.

^b Excluding participants A, B, C, and D with ADA with decreased exposure.

^c Median [individual data for participants A, B, C, and D, respectively] (Figures S1–S4).

^d Model‐based ABR were derived using a negative‐binomial regression model.

^e CIs were derived using the exact method.